Latest database descriptions

Primary Objective: evaluate the efficacy and safety of bevacizumab as first-line treatment in participants with colorectal cancer and potentially resectable liver metastases.
Secondary Objectives:
- To describe patients’ characteristics treated with Avastin®,
- To describe the subgroup of patients with unresected missing metastases, with or without surgery,
- To describe criteria used to define unresectability,
- To describe progression-free survival in all patients,
- To describe relapse-free survival in all resected patients with no DMD,
- To describe overall survival in all patients,
- To describe histopathological response in resected patients,
- To describe Avastin® treatment modalities,
- To describe safety profile of Avastin®.

Primary Objective: To assess in real life the Progression-Free Survival at a maximum of 36 months follow-up, in patients suffering from metastatic colorectal cancer and initiating a treatment with Avastin® combined with chemotherapy.
Secondary Objectives:
- To describe characteristics of patients treated with Avastin®
- To describe the use of Avastin® over the study period
- To assess the overall survival of patients treated with Avastin®
- To describe the Avastin® safety profile (serious adverse events and/or unexpected related to Avastin®, and/or adverse events of special interest)
- To describe the quality of life of patients treated with Avastin®.
Exploratory Objective:
A search for the prognostic factors of PFS and OS was performed using a Cox model in patients treated with 1st line of chemotherapy (overall and in the subgroup of patients with synchronous metastases). These factors were determined from the characteristics of patients at inclusion.

Primary Objective: Progression-free survival in patients aged >= 75 years with metastatic colorectal cancer initiating first line treatment with Avastin®
Secondary Objectives:
- To describe the demographic, clinical and nutritional profiles of the patients and their living conditions and degree of autonomy;
- To describe the change in autonomy criteria;
- To describe the OS;
- To describe Avastin® dosage and regimen;
- To describe the safety profile of Avastin®.

Primary Objective: To estimate the OS of patients treated with cobimetinib in combination with vemurafenib
Secondary Objectives:
- To assess the PFS
- To identify prognostic factors of OS
- To identify prognostic factors of PFS
- To describe response to treatment (overall assessment of the physician)
- To describe time to treatment discontinuation.
- To characterize the targeted AE of cobimetinib in combination with vemurafenib under real-world conditions of useTo describe the long term safety profile of cobimetinib in association with vemurafenib under real-world conditions of use
Exploratory Objectives:
- To describe population of patients treated with cobimetinib in combination with vemurafenib
- To describe the use of cobimetinib in combination with vemurafenib